Nomination committee for the 2020 Annual General Meeting
According to a decision by the Annual General Meeting 2019, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest shareholders in terms of voting rights at the end of December 2019.
At the end of December, the two largest shareholders were Cadila Pharmaceuticals Ltd. and Fårö Capital AB who both agreed to participate in the nomination committee work. The third largest shareholder has declined to participate in the nomination committee. The fourth largest shareholder is Lars Holmqvist, including companies, that have accepted to participate in the nomination process.
The Nomination Committee for the 2020 Annual General Meeting is thus made up of Christer Fåhraeus (appointed by Fårö Capital AB), Rajiv I Modi (appointed by Cadila Pharmaceuticals Ltd.), and Lars Holmqvist (appointed by Lars Holmqvist with companies).
Shareholders who wish to submit proposals to the Nomination Committee are invited to send an email to email@example.com.
For further information, please contact:
CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.